RxDoctor Payments Data

Savely Meyerzon, MD

Psychiatry · Brooklyn, NYNPI 1730357088

Payments from drug & device makers

$1,667in general payments, 2019–2025

Across 76 payments — averaging $21.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$518
  • Otsuka America Pharmaceutical, Inc.$418
  • Indivior Inc.$190
  • Lundbeck LLC$159
  • Sunovion Pharmaceuticals Inc.$123
  • Johnson & Johnson$92
  • plus $167 from 4 others

What the payments were for

  • Food & beverage$1,667100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,667 in reported general payments places this provider in the 80th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$460,276
Medicare patients
215
Services billed
3,925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole46$75,510
Invega SustennaPaliperidone Palmitate11$37,424
LunestaEszopiclone35$31,601
NamzaricMemantine Hcl/Donepezil Hcl49$28,209
SuboxoneBuprenorphine Hcl/Naloxone Hcl35$25,512
Effexor XrVenlafaxine Hcl12$22,060
LatudaLurasidone Hcl13$20,928
LexaproEscitalopram Oxalate23$14,502
LyricaPregabalin11$11,376
ZoloftSertraline Hcl13$10,974
ZubsolvBuprenorphine Hcl/Naloxone Hcl12$10,724
Lurasidone Hcl17$9,195
Mirtazapine744$9,060
TrintellixVortioxetine Hydrobromide16$7,369
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl30$5,956

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$418$75,51046 claims
AbbVieNamzaric, Lexapro$46$42,71172 claims
Johnson & JohnsonInvega Sustenna$92$37,42411 claims
Indivior Inc.Suboxone$190$25,51235 claims
Sunovion Pharmaceuticals Inc.Latuda$123$20,92813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →